Resalis Therapeutics
PrivateLast Round
Strategic
Oct 28, 2024
Total Funding Raised
$21.71M
Company Overview
Resalis Therapeutics is a biotechnology company developing non-coding RNA-based therapies for metabolic disorders such as obesity and fatty liver disease.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Resalis Therapeutics Comparables
Compare Resalis Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| AptamiR Therapeutics | 87% | |
| Rivus Pharmaceuticals | 78% | |
| EraCal Therapeutics | 75% |
Resalis Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Strategic | Oct 28, 2024 | ||||
| Series A | Jan 4, 2024 | ||||
| Seed | Feb 22, 2023 |
Key People
Founding team and executive leadership
Resalis Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Club degli Investitori | Seed, Series A |
| Claris Ventures | Series A, Seed |
| Sunstone Life Science Ventures | Series A |
| Italian Angels for Growth | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 28, 2024
Sanofi led a strategic funding round.
- Jan 4, 2024
$11M round led by Sunstone Life Science Ventures.
Recent news
Latest coverage and updates
- hiresSep 2, 2026
Resalis Therapeutics S.r.l. hired Diana M. Røpcke as Chief Medical Officer on Sep 2nd '26.
Resalis Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Resalis Therapeutics's valuation, stock price, and market status.
Is Resalis Therapeutics a public or private company?
Resalis Therapeutics is a private company.
What is the current stock price of Resalis Therapeutics?
Resalis Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Resalis Therapeutics worth (valuation)?
Valuation information for Resalis Therapeutics is not publicly available.
Can I buy Resalis Therapeutics stock?
Resalis Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Resalis Therapeutics's last funding round?
Resalis Therapeutics's most recent funding round was Strategic on October 28, 2024.
Who are the main investors in Resalis Therapeutics?
Key investors in Resalis Therapeutics include Claris Ventures, Sunstone Life Science Ventures.
Will Resalis Therapeutics IPO soon?
No public IPO plans have been announced for Resalis Therapeutics.
How can I track Resalis Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Resalis Therapeutics's secondary market activity and sign up for updates.